Concretely: survodutide · seven days.
I am trying to do this correctly the first time rather than learn it by getting it wrong.
I have already made one mistake here that cost me a vial, so I am being deliberately careful.
What does a defensible version of this look like in practice?
On the detail: the steady-state arithmetic is worth doing once, because it explains most of what people find confusing about weekly dosing.
Missing a dose by three days on a weekly schedule takes the trough down by less than a factor of 1.35, which is well inside the variation you would see between two on-time weeks. Missing it by five or more days is where the label instructions start to differ between agents, and the reason is how close the next scheduled dose is rather than any mechanistic threshold.
Escalating in response to a plateau is a specific and common error of reasoning. A plateau after four to six months is the expected trajectory in every trial in the class — the curve flattens because energy expenditure falls with mass, not because the receptor stopped working. A dose step may still be reasonable; "the loss stopped" is not by itself the reason.
SURMOUNT-1 used a twenty-week escalation of tirzepatide in 2.5 mg increments to maintenance doses of 5, 10 and 15 mg weekly, and reported a clear dose-response across those maintenance levels — which is the closest thing to evidence that the top of the ladder does more than the middle.
The short version: four-week steps because that is steady state, and the ladder is about the side effects, not the result.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsFor a compound with a seven-day half-life, dose timing is much less consequential than people expect and dose rate is much more consequential.
The maintenance question turns on what you are maintaining. If the objective is weight maintenance, the withdrawal-extension data suggests that a fraction of the therapeutic dose retains a substantial fraction of the effect. If the objective is the cardiovascular or renal endpoint, the trials that demonstrated those endpoints used the full dose, and extrapolating downward is not supported by anything.
In practice, holding at a step for longer than four weeks before escalating does appear to reduce cumulative gastrointestinal burden, which is unsurprising given that adverse events cluster in the one to two weeks after each increase. What it does not do is change where you end up, provided you get there.
The label instructions for a missed weekly dose differ between agents, and reading the actual prescribing information rather than a summary is worth the ten minutes — the thresholds are specific and the reasoning behind them is stated.
Escalate on tolerability, hold when it costs you, and do not confuse a flattening curve with a failing drug.
edited 18 Jul 2026 by leonid_marchuk — added the placebo-arm figures
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.